145 related articles for article (PubMed ID: 1562757)
1. Recent clinical experience with aldose reductase inhibitors.
Krans HM
J Diabetes Complications; 1992; 6(1):39-44. PubMed ID: 1562757
[TBL] [Abstract][Full Text] [Related]
2. Aldose reductase inhibitors: an update.
Tsai SC; Burnakis TG
Ann Pharmacother; 1993 Jun; 27(6):751-4. PubMed ID: 8329799
[TBL] [Abstract][Full Text] [Related]
3. Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Pfeifer MA; Schumer MP; Gelber DA
Diabetes; 1997 Sep; 46 Suppl 2():S82-9. PubMed ID: 9285505
[TBL] [Abstract][Full Text] [Related]
4. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
Greene DA
J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
[TBL] [Abstract][Full Text] [Related]
5. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
Hotta N; Sakamoto N
Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
[No Abstract] [Full Text] [Related]
6. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
van Gerven JM; Tjon-A-Tsien AM
Drugs Aging; 1995 Jan; 6(1):9-28. PubMed ID: 7696781
[TBL] [Abstract][Full Text] [Related]
7. Recent clinical experience with aldose reductase inhibitors.
Krans HM
Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
[No Abstract] [Full Text] [Related]
8. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
Jacobson M; Sharma YR; Cotlier E; Hollander JD
Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
[TBL] [Abstract][Full Text] [Related]
9. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors.
Bhatnagar A; Liu SQ; Das B; Ansari NH; Srivastava SK
Biochem Pharmacol; 1990 Mar; 39(6):1115-24. PubMed ID: 2157439
[TBL] [Abstract][Full Text] [Related]
10. Can aldose reductase inhibition ameliorate diabetic neuropathy?
González ER
JAMA; 1981 Sep; 246(11):1169-70. PubMed ID: 6790734
[No Abstract] [Full Text] [Related]
11. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
Brogard JM; Caro-Sampara F; Blicklé JF
Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879
[TBL] [Abstract][Full Text] [Related]
12. Effects of aldose reductase inhibitors on the progression of nerve damage.
Greene DA; Sima AA
Diabet Med; 1993; 10 Suppl 2():31S-32S. PubMed ID: 8334837
[No Abstract] [Full Text] [Related]
13. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Kador PF; Kinoshita JH; Sharpless NE
J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
[No Abstract] [Full Text] [Related]
14. Aldose reductase inhibitors and late complications of diabetes.
Benfield P
Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
[TBL] [Abstract][Full Text] [Related]
15. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
Jaspan JB; Towle VL; Maselli R; Herold K
Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
[TBL] [Abstract][Full Text] [Related]
16. The polyol pathway in retinal microangiopathy.
Robison WG; Kinoshita JH; Kador PF
Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
[TBL] [Abstract][Full Text] [Related]
17. Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
Beyer-Mears A; Murray FT; Cruz E; Rountree J; Sciadini M
Pharmacology; 1992; 45(5):285-91. PubMed ID: 1465475
[TBL] [Abstract][Full Text] [Related]
18. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
Chang WP; Dimitriadis E; Allen T; Dunlop ME; Cooper M; Larkins RG
Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibition for diabetic neuropathy.
Lancet; 1983 Oct; 2(8356):969. PubMed ID: 6138528
[No Abstract] [Full Text] [Related]
20. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
Hamada Y; Nakamura J
Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
